Starpharma today announced its SN-38 nanoparticle, DEP^® irinotecan in combination with an immuno-oncology (IO) agent (anti PD-1 antibody) showed superior anti-tumour activity and significant survival benefit in two colorectal cancer (CRC) models when compared to the anti PD-1 antibody alone. These results included improvement in both survival and efficacy in the particularly aggressive CT-26 CRC model.

The ABC’s 7:30 report interviewed Starpharma CEO Dr Jackie Fairley to discuss the importance of creating COVID-19 preventative products while the world waits for a vaccine to be developed. Dr Fairley discussed how Starparma’s patented dendrimer SPL7013 has shown significant anti-viral activity against SARS-CoV-2 (coronavirus) and how quickly a product using this ingredient could be brought to market given its approval and use in other marketed products.

Watch the full interview click here.

Alan  Kohler recently interviewed Starpharma CEO Dr Jackie Fairley on the ABC’s 7.30 report to discuss the importance of developing other methods of protection against  COVID-19 while we wait for a vaccine. Jackie also discusses how Starpharma’s patented dendrimer SPL7013 is being developed for use in an antiviral nasal spray to prevent COVID-19 infection.

Watch the full interview here: https://www.abc.net.au/7.30/how-long-will-the-economy-take-to-recover/12394342

Starpharma today announced that five posters featuring products based on Starpharma’s DEP^® platform have been presented at the AACR (American Association for Cancer Research) Annual Meeting. The AACR Annual Meeting brings together leading cancer research and medicine from institutions all over the world and is an important forum for both raising product awareness and commercial interactions.

Finance and market news website AusBiz interviewed Starpharma CEO Dr Jackie Fairley to discuss the company’s first radiotherapeutic candidate, DEP^® lutetium. The candidate showed highly statistically significant anticancer activity, tumour regression and 100% survival in a human prostate cancer model. The interview also covered the company’s latest VivaGel® BV launch in Central and Eastern Europe.

To watch the full interview click here.

A new study using Australian data showed a causal link between female leadership and business performance. Starpharma is one of only 15 ASX300 companies to have a female CEO and Dr Jackie Fairley spoke with SBS about the importance of having senior female leaders in a corporate setting.

For the full interview click here.

Starpharma today announced that a pre-recorded presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 18 June 2020 (US ET) as part of OTCQX’s Virtual Investor Conference for Global Mid-cap and Large-cap Companies. The conference is primarily attended  by US-based  retail investors, as well as advisors.

Starpharma today announced results from its first radiotherapeutic candidate, DEP^® lutetium. DEP^® lutetium is a patented nanoparticle which incorporates the radioisotope Lutetium-177 on a DEP^® dendrimer scaffold. 

Starpharma today announced that VivaGel^® BV has been launched in Central and Eastern European (CEE) region. This launch follows European launches in Germany, UK and several other European countries.